This study is not accepting new patients

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

a study on Epilepsy Dravet Syndrome

Summary

Eligibility
for people ages 2 years and up (full criteria)
Location
at UCLA
Dates
study started

Description

Summary

The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.

Official Title

Extended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory Epilepsies

Keywords

Epilepsies, Myoclonic, Drug Resistant Epilepsy, Extended Access Program, Expanded Access Program, Dravet Syndrome, Refractory Epilepsies, Lorcaserin, Epilepsy, Myoclonic Epilepsies

Eligibility

You can join if…

Open to people ages 2 years and up

  1. Confirmed diagnosis of Dravet syndrome (according to Recommendation from a North American Consensus Panel, 2017) or other refractory epilepsy (per the judgment of the treating physician)
  2. Male or female, age at least 2 years at the time of informed consent
  3. Currently treated with lorcaserin, that the treatment is for Dravet syndrome or other refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has completed Study E2023-A001-304
  4. Has a clinical benefit from lorcaserin in the opinion of the treating physician

You CAN'T join if...

None

Locations

  • David Geffen School of Medicine, UCLA Mattel Children's Hospital not accepting new patients
    Los Angeles California 90095 United States
  • BC Children's Hospital not accepting new patients
    Vancouver British Columbia V6H 3N1 Canada

Details

Status
not accepting new patients
Start Date
Sponsor
Eisai Inc.
ID
NCT04457687
Study Type
Expanded Access
Last Updated